JP2014513722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513722A5 JP2014513722A5 JP2014511390A JP2014511390A JP2014513722A5 JP 2014513722 A5 JP2014513722 A5 JP 2014513722A5 JP 2014511390 A JP2014511390 A JP 2014511390A JP 2014511390 A JP2014511390 A JP 2014511390A JP 2014513722 A5 JP2014513722 A5 JP 2014513722A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- therapeutic agent
- patient
- increasing
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 claims 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 102000045921 human GAA Human genes 0.000 claims 1
- 102000043404 human GLA Human genes 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 210000002707 regulatory b cell Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486697P | 2011-05-16 | 2011-05-16 | |
| US61/486,697 | 2011-05-16 | ||
| PCT/US2012/036405 WO2012158362A1 (en) | 2011-05-16 | 2012-05-03 | Induction of immune tolerance by using methotrexate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017040046A Division JP6381707B2 (ja) | 2011-05-16 | 2017-03-03 | メトトレキサートを用いる免疫寛容の誘導 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513722A JP2014513722A (ja) | 2014-06-05 |
| JP2014513722A5 true JP2014513722A5 (enExample) | 2015-06-25 |
| JP6174572B2 JP6174572B2 (ja) | 2017-08-02 |
Family
ID=47177257
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511390A Active JP6174572B2 (ja) | 2011-05-16 | 2012-05-03 | メトトレキサートを用いる免疫寛容の誘導 |
| JP2017040046A Active JP6381707B2 (ja) | 2011-05-16 | 2017-03-03 | メトトレキサートを用いる免疫寛容の誘導 |
| JP2018145564A Active JP6694020B2 (ja) | 2011-05-16 | 2018-08-02 | メトトレキサートを用いる免疫寛容の誘導 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017040046A Active JP6381707B2 (ja) | 2011-05-16 | 2017-03-03 | メトトレキサートを用いる免疫寛容の誘導 |
| JP2018145564A Active JP6694020B2 (ja) | 2011-05-16 | 2018-08-02 | メトトレキサートを用いる免疫寛容の誘導 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20140135337A1 (enExample) |
| EP (2) | EP2709627B1 (enExample) |
| JP (3) | JP6174572B2 (enExample) |
| KR (3) | KR102316283B1 (enExample) |
| CN (4) | CN110124039A (enExample) |
| AU (1) | AU2012256281B2 (enExample) |
| BR (1) | BR112013029501A2 (enExample) |
| CA (1) | CA2835819A1 (enExample) |
| CL (1) | CL2013003298A1 (enExample) |
| CO (1) | CO6841993A2 (enExample) |
| DO (1) | DOP2013000268A (enExample) |
| EC (1) | ECSP13013081A (enExample) |
| ES (1) | ES2836823T3 (enExample) |
| GT (1) | GT201300278A (enExample) |
| IL (2) | IL229245B (enExample) |
| MA (1) | MA35165B1 (enExample) |
| MX (1) | MX2013013445A (enExample) |
| MY (1) | MY173304A (enExample) |
| NI (1) | NI201300121A (enExample) |
| PE (1) | PE20140469A1 (enExample) |
| PH (1) | PH12013502256A1 (enExample) |
| PT (1) | PT2709627T (enExample) |
| RU (1) | RU2674036C2 (enExample) |
| SG (1) | SG194802A1 (enExample) |
| TN (1) | TN2013000472A1 (enExample) |
| UA (1) | UA117556C2 (enExample) |
| WO (1) | WO2012158362A1 (enExample) |
| ZA (1) | ZA201308315B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809282B2 (en) * | 2010-05-06 | 2014-08-19 | Duke University | Method of reducing titers of antibodies specific for a therapeutic agent |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| CA2835819A1 (en) | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
| CA2910584A1 (en) * | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells |
| KR102631173B1 (ko) * | 2013-06-04 | 2024-01-31 | 셀렉타 바이오사이언시즈, 인크. | 비-면역억제성 항원 특이적 면역요법제의 반복 투여 |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| JP2016213236A (ja) * | 2015-04-30 | 2016-12-15 | 日東電工株式会社 | 半導体装置用フィルム、及び、半導体装置の製造方法 |
| EP3592389B1 (en) | 2017-03-11 | 2025-05-07 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US11944628B2 (en) * | 2017-05-12 | 2024-04-02 | Duke University | Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy |
| TWI821227B (zh) * | 2017-12-22 | 2023-11-11 | 美商健臻公司 | 胺甲喋呤誘發的免疫耐受性之生物標記 |
| EP4100120A1 (en) | 2020-02-08 | 2022-12-14 | Genzyme Corporation | Compositions and methods for treating pompe disease |
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080325A (en) | 1976-11-17 | 1978-03-21 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of methotrexate |
| US4558690A (en) | 1982-01-26 | 1985-12-17 | University Of Scranton | Method of administration of chemotherapy to tumors |
| US5108987A (en) | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
| US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| DE4000154A1 (de) | 1990-01-04 | 1991-07-11 | Symbiotec Gmbh | Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| EP1724287A4 (en) | 2004-03-05 | 2010-10-27 | Denki Kagaku Kogyo Kk | HYALURONIC / METHOTREXATE CONNECTION |
| US7884196B2 (en) | 2004-10-06 | 2011-02-08 | Oliver Lawless | Vaccine composition comprising methylated DNA and immunomodulatory motifs |
| EP1988882B1 (en) * | 2006-03-02 | 2014-12-17 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| WO2008094937A2 (en) | 2007-01-29 | 2008-08-07 | Joslin Diabetes Center, Inc. | Methods of modulating angiogenesis |
| WO2009073146A2 (en) * | 2007-11-29 | 2009-06-11 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
| US7914785B2 (en) * | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP2077281A1 (en) * | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| ES2784830T3 (es) | 2008-10-08 | 2020-10-01 | Cambridge Entpr Ltd | Métodos para el diagnóstico y tratamiento de enfermedad autoinmune como consecuencia de esclerosis múltiple |
| AU2009313053A1 (en) | 2008-11-07 | 2010-05-14 | 4Sc Ag | Combinational therapy comprising DHODH inhibitor and methotrexate for treating autoimmune disease |
| CA2835819A1 (en) | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
-
2012
- 2012-05-03 CA CA2835819A patent/CA2835819A1/en not_active Abandoned
- 2012-05-03 KR KR1020207027913A patent/KR102316283B1/ko active Active
- 2012-05-03 WO PCT/US2012/036405 patent/WO2012158362A1/en not_active Ceased
- 2012-05-03 EP EP12785624.3A patent/EP2709627B1/en active Active
- 2012-05-03 CN CN201910138372.3A patent/CN110124039A/zh active Pending
- 2012-05-03 CN CN201811398468.5A patent/CN109620830A/zh active Pending
- 2012-05-03 BR BR112013029501A patent/BR112013029501A2/pt not_active Application Discontinuation
- 2012-05-03 KR KR1020137032882A patent/KR20140040744A/ko not_active Ceased
- 2012-05-03 EP EP20197579.4A patent/EP3824890A1/en active Pending
- 2012-05-03 CN CN201280035299.3A patent/CN103648501A/zh active Pending
- 2012-05-03 MX MX2013013445A patent/MX2013013445A/es unknown
- 2012-05-03 SG SG2013082003A patent/SG194802A1/en unknown
- 2012-05-03 RU RU2013155618A patent/RU2674036C2/ru active
- 2012-05-03 UA UAA201314626A patent/UA117556C2/uk unknown
- 2012-05-03 US US14/116,486 patent/US20140135337A1/en not_active Abandoned
- 2012-05-03 ES ES12785624T patent/ES2836823T3/es active Active
- 2012-05-03 JP JP2014511390A patent/JP6174572B2/ja active Active
- 2012-05-03 AU AU2012256281A patent/AU2012256281B2/en active Active
- 2012-05-03 CN CN202011422509.7A patent/CN113209288A/zh active Pending
- 2012-05-03 PE PE2013002499A patent/PE20140469A1/es not_active Application Discontinuation
- 2012-05-03 KR KR1020197033979A patent/KR102163285B1/ko active Active
- 2012-05-03 PH PH1/2013/502256A patent/PH12013502256A1/en unknown
- 2012-05-03 PT PT127856243T patent/PT2709627T/pt unknown
- 2012-05-03 MY MYPI2013003998A patent/MY173304A/en unknown
-
2013
- 2013-11-04 IL IL229245A patent/IL229245B/en active IP Right Grant
- 2013-11-06 ZA ZA2013/08315A patent/ZA201308315B/en unknown
- 2013-11-13 TN TNP2013000472A patent/TN2013000472A1/fr unknown
- 2013-11-14 GT GT201300278A patent/GT201300278A/es unknown
- 2013-11-14 NI NI201300121A patent/NI201300121A/es unknown
- 2013-11-15 CL CL2013003298A patent/CL2013003298A1/es unknown
- 2013-11-15 DO DO2013000268A patent/DOP2013000268A/es unknown
- 2013-12-04 MA MA36522A patent/MA35165B1/fr unknown
- 2013-12-05 CO CO13286019A patent/CO6841993A2/es not_active Application Discontinuation
- 2013-12-13 EC ECSP13013081 patent/ECSP13013081A/es unknown
-
2017
- 2017-03-03 JP JP2017040046A patent/JP6381707B2/ja active Active
-
2018
- 2018-08-02 JP JP2018145564A patent/JP6694020B2/ja active Active
-
2020
- 2020-03-24 US US16/828,407 patent/US11672802B2/en active Active
- 2020-08-23 IL IL276879A patent/IL276879B/en unknown
-
2023
- 2023-04-28 US US18/141,128 patent/US20230372347A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513722A5 (enExample) | ||
| RU2013155618A (ru) | Индукция иммунологической толерантности, используя метотрексат | |
| EA201891154A1 (ru) | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей | |
| JP2011225596A5 (enExample) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| JP2015524444A5 (enExample) | ||
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| RU2015120216A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2015524472A5 (enExample) | ||
| MY157564A (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| JP2013537539A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
| WO2009040072A3 (en) | Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis | |
| JP2013510169A5 (enExample) | ||
| JP2017501140A5 (enExample) | ||
| JP2014532722A5 (enExample) | ||
| FR2996838B1 (fr) | Procede de preparation d'un oxyde mixte de titane et de niobium par traitement solvothermal ; electrode et accumulateur au lithium comprenant ledit oxyde mixte | |
| HRP20161147T1 (hr) | Farmaceutski sastav i postupak njegove proizvodnje | |
| RU2014112324A (ru) | Применение органического соединения для лечения синдрома нунан | |
| JP2013523886A5 (enExample) |